Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02113878
PHASE1

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Sponsor: Dana-Farber Cancer Institute

View on ClinicalTrials.gov

Summary

This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.

Official title: A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

23

Start Date

2014-09-29

Completion Date

2022-01-01

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

DRUG

BKM120

BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

DRUG

Cisplatin

Cisplatin is a chemotherapy drug

RADIATION

Intensity-modulated radiotherapy (IMRT)

IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells

Locations (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States